{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:54:56Z","timestamp":1791467696677,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03429-w","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:43:43Z","timestamp":1791459823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenic cell death: synergizing ferroptosis and cuproptosis to overcome immunotherapy resistance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-4650","authenticated-orcid":false,"given":"Mamdouh A.","family":"Ragab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Seliem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"3429_CR1","doi-asserted-by":"crossref","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014. 515(7528): pp. 568\u2013571.","DOI":"10.1038\/nature13954"},{"issue":"1","key":"3429_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-025-06121-1","volume":"23","author":"Y Cong","year":"2025","unstructured":"Cong Y, Li N, Zhang Z, Shang Y, Zhao H. Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications. J Transl Med. 2025;23(1):104.","journal-title":"J Transl Med"},{"issue":"5","key":"3429_CR3","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1038\/cddis.2013.156","volume":"4","author":"O Krysko","year":"2013","unstructured":"Krysko O, L\u00f8ve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4(5):e631.","journal-title":"Cell Death Dis"},{"key":"3429_CR4","doi-asserted-by":"publisher","first-page":"1608975","DOI":"10.3389\/fmed.2025.1608975","volume":"12","author":"S Huang","year":"2025","unstructured":"Huang S, Sun Y, Yu X, Ren X, Wang L, Sun Y, Deng A. Ferroptosis in ocular diseases: mechanisms, crosstalk with other cell death pathways, and therapeutic prospects. Front Med. 2025;12:1608975.","journal-title":"Front Med"},{"key":"3429_CR5","doi-asserted-by":"publisher","first-page":"116115","DOI":"10.1016\/j.biopha.2023.116115","volume":"171","author":"N Liu","year":"2024","unstructured":"Liu N, Chen M. Crosstalk between ferroptosis and cuproptosis: From mechanism to potential clinical application. Biomed Pharmacother. 2024;171:116115.","journal-title":"Biomed Pharmacother"},{"key":"3429_CR6","doi-asserted-by":"crossref","unstructured":"Wang T, Zhou X, Yin X, Zhang A, Fan Y, Chen K, Tao H, Tang Z, Zhang P, He X, Yin L. From mitochondrial dysregulation to ferroptosis: Exploring new strategies and challenges in radioimmunotherapy (Review). Int J Oncol, 2025. 67(3):76.","DOI":"10.3892\/ijo.2025.5781"},{"key":"3429_CR7","doi-asserted-by":"publisher","first-page":"1706557","DOI":"10.3389\/fimmu.2025.1706557","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao X, Guan S. Epitranscriptomic control of cancer immunity and therapy resistance. Front Immunol. 2025;16:1706557.","journal-title":"Front Immunol"},{"issue":"1","key":"3429_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41420-023-01645-1","volume":"9","author":"X Chen","year":"2023","unstructured":"Chen X, Zhang L, He Y, Huang S, Chen S, Zhao W, Yu D. Regulation of m(6)A modification on ferroptosis and its potential significance in radiosensitization. Cell Death Discov. 2023;9(1):343.","journal-title":"Cell Death Discov"},{"issue":"5","key":"3429_CR9","first-page":"1060","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS. Ferroptosis: iron-dependent form nonapoptotic cell death cell. 2012;149(5):1060\u201372.","journal-title":"Ferroptosis: iron-dependent form nonapoptotic cell death cell"},{"key":"3429_CR10","doi-asserted-by":"publisher","first-page":"7449941","DOI":"10.1155\/2022\/7449941","volume":"2022","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liu Z, Le Y, Gu Z, Zhao H. Iron-Sulfur Clusters: A Key Factor of Regulated Cell Death in Cancer. Oxid Med Cell Longev. 2022;2022:7449941.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"3429_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gasc\u00f3n S, Hatzios SK, Kagan VE. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385.","journal-title":"Cell"},{"issue":"1","key":"3429_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43556-023-00142-2","volume":"4","author":"S Feng","year":"2023","unstructured":"Feng S, Tang D, Wang Y, Li X, Bao H, Tang C, Dong X, Li X, Yang Q, Yan Y, Yin Z, Shang T, Zheng K, Huang X, Wei Z, Wang K, Qi S. The mechanism of ferroptosis and its related diseases. Mol Biomed. 2023;4(1):33.","journal-title":"Mol Biomed"},{"key":"3429_CR13","doi-asserted-by":"publisher","first-page":"1329147","DOI":"10.3389\/fcell.2023.1329147","volume":"11","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Lin R, Lu S, Rong L, Xue Y, Fang Y. Understanding the unique mechanism of ferroptosis: a promising therapeutic target. Front Cell Dev Biology. 2024;11:1329147.","journal-title":"Front Cell Dev Biology"},{"key":"3429_CR14","doi-asserted-by":"crossref","unstructured":"Springer C, Humayun D, Skouta R. Cuproptosis: Unraveling the mechanisms of copper-induced cell death and its implication in cancer therapy. Cancers (Basel), 2024. 16(3):647.","DOI":"10.3390\/cancers16030647"},{"issue":"6586","key":"3429_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"key":"3429_CR16","doi-asserted-by":"crossref","unstructured":"Wang J, Li J, Liu J, Chan KY, Lee HS, Lin KN, Wang CC, Lau TS. Interplay of ferroptosis and cuproptosis in cancer: dissecting metal-driven mechanisms for therapeutic potentials. Cancers (Basel), 2024;16(3):512.","DOI":"10.3390\/cancers16030512"},{"issue":"5","key":"3429_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417\u20138.","journal-title":"Cell Res"},{"key":"3429_CR18","doi-asserted-by":"crossref","unstructured":"Du J, Huang Z, Li Y, Ren X, Zhou C, Liu R, Zhang P, Lei G, Lu J, Li J, Tan G. Copper exerts cytotoxicity through inhibition of iron-sulfur cluster biogenesis on ISCA1\/ISCA2\/ISCU assembly proteins. Free Radical Biology and Medicine; 2023. p. 204.","DOI":"10.1016\/j.freeradbiomed.2023.05.017"},{"key":"3429_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.freeradbiomed.2023.05.017","volume":"204","author":"J Du","year":"2023","unstructured":"Du J, Huang Z, Li Y, Ren X, Zhou C, Liu R, Zhang P, Lei G, Lyu J, Li J. Copper exerts cytotoxicity through inhibition of iron-sulfur cluster biogenesis on ISCA1\/ISCA2\/ISCU assembly proteins. Free Radic Biol Med. 2023;204:359\u201373.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3429_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-025-06121-1","volume":"23","author":"Y Cong","year":"2025","unstructured":"Cong Y, Li N, Zhang Z, Shang Y, Zhao H. Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications. J translational Med. 2025;23(1):104.","journal-title":"J translational Med"},{"issue":"22","key":"3429_CR21","doi-asserted-by":"publisher","first-page":"eabg4302","DOI":"10.1126\/sciadv.abg4302","volume":"7","author":"EM Terzi","year":"2021","unstructured":"Terzi EM, Sviderskiy VO, Alvarez SW, Whiten GC, Possemato R. Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5. Sci Adv. 2021;7(22):eabg4302.","journal-title":"Sci Adv"},{"key":"3429_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2021.09.013","volume":"176","author":"O Karmi","year":"2021","unstructured":"Karmi O, Sohn Y-S, Zandalinas SI, Rowland L, King SD, Nechushtai R, Mittler R. Disrupting CISD2 function in cancer cells primarily impacts mitochondrial labile iron levels and triggers TXNIP expression. Free Radic Biol Med. 2021;176:92\u2013104.","journal-title":"Free Radic Biol Med"},{"key":"3429_CR23","first-page":"1390263","volume":"15","author":"K Arimoto","year":"2024","unstructured":"Arimoto K, Miyauchi M, Liu, Zhang D-E. Emerging role immunogenic cell death cancer immunotherapy Front Immunol. 2024;15:1390263.","journal-title":"Emerging role immunogenic cell death cancer immunotherapy Front Immunol"},{"issue":"1","key":"3429_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12943-024-02132-6","volume":"23","author":"JX Shi","year":"2024","unstructured":"Shi JX, Zhang ZC, Yin HZ, Piao XJ, Liu CH, Liu QJ, Zhang JC, Zhou WX, Liu FC, Yang F, Wang YF, Liu H. RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy. Mol Cancer. 2024;23(1):213.","journal-title":"Mol Cancer"},{"key":"3429_CR25","doi-asserted-by":"publisher","first-page":"996307","DOI":"10.3389\/fcell.2022.996307","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Liu Y, Wang Y, Kang R, Tang D. HMGB1 is a mediator of cuproptosis-related sterile inflammation. Front Cell Dev Biology. 2022;10:996307.","journal-title":"Front Cell Dev Biology"},{"issue":"7397","key":"3429_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201\u20136.","journal-title":"Nature"},{"issue":"2","key":"3429_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X. A METTL3\u2013METTL14 complex mediates mammalian nuclear RNA N 6-adenosine methylation. Nat Chem Biol. 2014;10(2):93\u20135.","journal-title":"Nat Chem Biol"},{"issue":"5","key":"3429_CR28","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1002\/ctm2.778","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, He J, Sun G, Huang N, Bian Z, Xu C, Zhang Y, Cui Z, Xu W, Sun F. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin translational Med. 2022;12(5):e778.","journal-title":"Clin translational Med"},{"key":"3429_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2021.03.023","volume":"168","author":"L Ma","year":"2021","unstructured":"Ma L, Zhang X, Yu K, Xu X, Chen T, Shi Y, Wang Y, Qiu S, Guo S, Cui J. Targeting SLC3A2 subunit of system XC\u2009\u2013\u2009is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma. Free Radic Biol Med. 2021;168:25\u201343.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3429_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s42003-025-09497-4","volume":"9","author":"Q Jiang","year":"2026","unstructured":"Jiang Q, Peng C, Mao W, Yu Z, Feng Y, Li Y, Zhu J, Zhao J, Liao D, Sun T. METTL3-mediated m6A modification of FDX1 confers resistance to cuproptosis and promotes hepatocellular carcinoma progression. Commun Biol. 2026;9(1):222.","journal-title":"Commun Biol"},{"key":"3429_CR31","doi-asserted-by":"publisher","first-page":"tfaf123","DOI":"10.1093\/toxres\/tfaf123","volume":"14","author":"B Yang","year":"2025","unstructured":"Yang B, Pan M, Tao T, Chen K, Kong D, Hao J, Liao G, Liu F, Gong H. Tanshinone IIA promotes METTL3\/METTL14-mediated FDX1 m6A modification to induce cuproptosis in bladder cancer. Toxicol Res. 2025;14:tfaf123.","journal-title":"Toxicol Res"},{"issue":"2","key":"3429_CR32","doi-asserted-by":"publisher","first-page":"e1012707","DOI":"10.1371\/journal.pcbi.1012707","volume":"21","author":"MC Lau","year":"2025","unstructured":"Lau MC, Borowsky J, V\u00e4yrynen JP, Haruki K, Zhao M, Dias Costa A, Gu S, Da Silva A, Ugai T, Arima K. Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment. PLoS Comput Biol. 2025;21(2):e1012707.","journal-title":"PLoS Comput Biol"},{"issue":"8","key":"3429_CR33","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jid.2023.01.027","volume":"143","author":"G Wang","year":"2023","unstructured":"Wang G, Zeng D, Sweren E, Miao Y, Chen R, Chen J, Wang J, Liao W, Hu Z, Kang S. N6-methyladenosine RNA methylation correlates with immune microenvironment and immunotherapy response of melanoma. J Invest Dermatology. 2023;143(8):1579\u201390. e5.","journal-title":"J Invest Dermatology"},{"issue":"8","key":"3429_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jid.2023.01.027","volume":"143","author":"G Wang","year":"2023","unstructured":"Wang G, Zeng D, Sweren E, Miao Y, Chen R, Chen J, Wang J, Liao W, Hu Z, Kang S, Garza LA. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma. J Invest Dermatol. 2023;143(8):1579\u2013e15905.","journal-title":"J Invest Dermatol"},{"key":"3429_CR35","doi-asserted-by":"publisher","first-page":"1572810","DOI":"10.3389\/fimmu.2025.1572810","volume":"16","author":"P Song","year":"2025","unstructured":"Song P, Ye J, Zhang H, Li Y, Cao R, Feng Y, Zhang L, Sun M. Cross-talk of m6A methylation modification and the tumor microenvironment composition in esophageal cancer. Front Immunol. 2025;16:1572810.","journal-title":"Front Immunol"},{"key":"3429_CR36","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.2147\/IJN.S563439","volume":"20","author":"Y Chen","year":"2025","unstructured":"Chen Y, Wang J, Zheng D, Zhang W. Tumor Microenvironment Reprogramming via Copper-Enriched Black Phosphorus Nanoplatform for Cuproptosis-Sensitized Low-Dose Radioimmunotherapy. Int J Nanomed. 2025;20:14551\u201369.","journal-title":"Int J Nanomed"},{"issue":"13","key":"3429_CR37","doi-asserted-by":"publisher","first-page":"12943","DOI":"10.18632\/aging.103378","volume":"12","author":"H Dong","year":"2020","unstructured":"Dong H, Qiang Z, Chai D, Peng J, Xia Y, Hu R, Jiang H. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging. 2020;12(13):12943.","journal-title":"Aging"},{"issue":"7354","key":"3429_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106\u20139.","journal-title":"Nature"},{"key":"3429_CR39","doi-asserted-by":"crossref","unstructured":"Tabnak P, Ebrahimnezhad M, HajiEsmailPoor Z. Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy. Cell Death Dis, 2026. 17(1) 299.","DOI":"10.1038\/s41419-026-08796-w"},{"issue":"7545","key":"3429_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57\u201362.","journal-title":"Nature"},{"issue":"7498","key":"3429_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature13148","volume":"509","author":"JD Mancias","year":"2014","unstructured":"Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105\u20139.","journal-title":"Nature"},{"key":"3429_CR42","doi-asserted-by":"publisher","first-page":"1527286","DOI":"10.3389\/fphar.2024.1527286","volume":"15","author":"L Xiang","year":"2025","unstructured":"Xiang L, Li Q, Guan Z, Wang G, Yu X, Zhang X, Zhang G, Hu J, Yang X, Li M. Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR\/PI3K\/AKT\/GPX4 signalling axis. Front Pharmacol. 2025;15:1527286.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3429_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao M-T. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","journal-title":"Cancer Cell"},{"issue":"4","key":"3429_CR44","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.7150\/ijms.127886","volume":"23","author":"X Zhang","year":"2026","unstructured":"Zhang X, Zheng D, Chu T, Yang D, Zhang K, Liang S, Yang L, Ma W. IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells. Int J Med Sci. 2026;23(4):1243.","journal-title":"Int J Med Sci"},{"issue":"9","key":"3429_CR45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","volume":"31","author":"SJ O\u2019Day","year":"2013","unstructured":"O\u2019Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211\u20138.","journal-title":"J Clin Oncol"},{"issue":"6586","key":"3429_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, Eaton JK, Frenkel E, Kocak M, Corsello SM, Lutsenko S, Kanarek N, Santagata S, Golub TR. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"key":"3429_CR47","doi-asserted-by":"crossref","unstructured":"Huang W, Wu Y, Zhu J, Luo N, Wang C, Liu S, Cheng Z. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas. Front Mol Biosci. 2023;10;963639.","DOI":"10.3389\/fmolb.2023.963639"},{"issue":"3","key":"3429_CR48","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.7150\/thno.121988","volume":"16","author":"X Chen","year":"2026","unstructured":"Chen X, Wang Q, Zhang H, Wang Y, Zhu H. Metal homeostasis as a therapeutic lever: advancing metalloimmunology to remodel the tumor microenvironment and enhance cancer immunotherapy. Theranostics. 2026;16(3):1350.","journal-title":"Theranostics"},{"issue":"11","key":"3429_CR49","doi-asserted-by":"publisher","first-page":"e0251957","DOI":"10.1371\/journal.pone.0251957","volume":"16","author":"R Serra","year":"2021","unstructured":"Serra R, Zhao T, Huq S, Gorelick NL, Casaos J, Cecia A, Mangraviti A, Eberhart C, Bai R, Olivi A. Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model. PLoS ONE. 2021;16(11):e0251957.","journal-title":"PLoS ONE"},{"key":"3429_CR50","doi-asserted-by":"crossref","unstructured":"Li P, Sun Q, Bai S, Wang H, Zhao L. Combination of the cuproptosis inducer disulfiram and anti\u2013PD\u2013L1 abolishes NSCLC resistance by ATP7B to regulate the HIF\u20131 signaling pathway. Int J Mol Med. 2024;53(2):19.","DOI":"10.3892\/ijmm.2023.5343"},{"issue":"4","key":"3429_CR51","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.7150\/ijbs.105575","volume":"21","author":"M Yuan","year":"2025","unstructured":"Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y, Wang J, Ji M, Hou P. Disulfiram\/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. Int J Biol Sci. 2025;21(4):1730\u201348.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"3429_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jn\/127.2.257","volume":"127","author":"RG Hopkins","year":"1997","unstructured":"Hopkins RG, Failla ML. Copper deficiency reduces interleukin-2 (IL-2) production and IL-2 mRNA in human T-lymphocytes. J Nutr. 1997;127(2):257\u201362.","journal-title":"J Nutr"},{"issue":"1","key":"3429_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/nu17010117","volume":"17","author":"X Li","year":"2024","unstructured":"Li X, Zeng X, Yang W, Ren P, Zhai H, Yin H. Impacts of copper deficiency on oxidative stress and immune function in mouse spleen. Nutrients. 2024;17(1):117.","journal-title":"Nutrients"},{"key":"3429_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fimmu.2016.00032","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Ertl HC. Starved and asphyxiated: how can CD8\u2009+\u2009T cells within a tumor microenvironment prevent tumor progression. Front Immunol. 2016;7:32.","journal-title":"Front Immunol"},{"key":"3429_CR55","doi-asserted-by":"crossref","unstructured":"Ma, X., L. Xiao, L. Liu, L. Ye, P. Su, E. Bi, Q. Wang, M. Yang, J. Qian, and Q. Yi,CD36-mediated ferroptosis dampens intratumoral CD8\u2009<\u2009sup>+\u2009T\u00a0cell effector function and impairs their antitumor ability. Cell Metabolism, 2021. 33(5): pp. 1001\u20131012.e5.","DOI":"10.1016\/j.cmet.2021.02.015"},{"issue":"9","key":"3429_CR56","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","volume":"31","author":"SJ O\u2019Day","year":"2013","unstructured":"O\u2019Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211\u20138.","journal-title":"J Clin Oncol"},{"key":"3429_CR57","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.12688\/f1000research.16786.1","volume":"7","author":"AS Jakola","year":"2018","unstructured":"Jakola AS, Werlenius K, Mudaisi M, Hylin S, Kinhult S, Bartek J Jr, Salvesen \u00d8, Carlsen SM, Strand\u00e9us M, Lindskog M. Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial. F1000Research. 2018;7:1797.","journal-title":"F1000Research"},{"issue":"2","key":"3429_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11523-016-0467-0","volume":"12","author":"JM Hubbard","year":"2017","unstructured":"Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I\/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017;12(2):201\u20139.","journal-title":"Target Oncol"},{"issue":"5","key":"3429_CR59","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00280-013-2118-9","volume":"71","author":"JA Chan","year":"2013","unstructured":"Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2013;71(5):1241\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3429_CR60","doi-asserted-by":"crossref","unstructured":"Liu Y, Lin W, Yang Y, Shao J, Zhao H, Wang G, Shen A. Role of cuproptosis-related gene in lung adenocarcinoma. Front Oncol, 2022. Volume 12\u20132022.","DOI":"10.3389\/fonc.2022.1080985"},{"key":"3429_CR61","doi-asserted-by":"crossref","unstructured":"Huo Y, Wang D, Yang S, Xu Y, Qin G, Zhao C, Lei Q, Zhao Q, Liu Y, Guo K, Ouyang S, Sun T, Wang H, Fan F, Han N, Liu H, Chen H, Miao L, Liu L, Duan Y, Lv W, Liu L, Zhang Z, Cang S, Wang L, Zhang Y. Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC. J Immunother Cancer, 2024. 12(12).","DOI":"10.1136\/jitc-2024-009627"},{"key":"3429_CR62","doi-asserted-by":"crossref","unstructured":"Lee SS-Y, Pagacz J, Averbek S, Scholten D, Liu Y, Kron SJ. Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation. bioRxiv, 2024: p. 2024.08.06.606845.","DOI":"10.1101\/2024.08.06.606845"},{"key":"3429_CR63","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wang, J., Zheng, D., & Zhang, W. (2025). Tumor Microenvironment Reprogramming via Copper-Enriched Black Phosphorus Nanoplatform for Cuproptosis-Sensitized Low-Dose Radioimmunotherapy. International Journal of Nanomedicine, 20, 14551\u201314569.","DOI":"10.2147\/IJN.S563439"},{"issue":"23","key":"3429_CR64","doi-asserted-by":"publisher","first-page":"2310309","DOI":"10.1002\/advs.202310309","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Liu J, Chen Y, Weichselbaum RR, Lin W. Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy. Adv Sci. 2024;11(23):2310309.","journal-title":"Adv Sci"},{"issue":"1","key":"3429_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","volume":"4","author":"A Cz\u0142onkowska","year":"2018","unstructured":"Cz\u0142onkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, Rybakowski JK, Weiss KH, Schilsky ML. Wilson disease. Nat reviews Disease primers. 2018;4(1):21.","journal-title":"Nat reviews Disease primers"},{"issue":"4","key":"3429_CR66","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1203\/01.pdr.0000203098.77573.39","volume":"59","author":"S Attri","year":"2006","unstructured":"Attri S, Sharma N, Jahagirdar S, Thapa BR, Prasad R. Erythrocyte metabolism and antioxidant status of patients with Wilson disease with hemolytic anemia. Pediatr Res. 2006;59(4):593\u20137.","journal-title":"Pediatr Res"},{"issue":"12","key":"3429_CR67","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180\u201391.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"3429_CR68","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023;33(12):1077\u201387.","journal-title":"Trends Cell Biol"},{"issue":"Supplement1","key":"3429_CR69","doi-asserted-by":"publisher","first-page":"16608","DOI":"10.4049\/jimmunol.208.Supp.166.08","volume":"208","author":"AH Mandarano","year":"2022","unstructured":"Mandarano AH, McGargill MA. Copper homeostasis is critical for T cell activation. J Immunol. 2022;208(Supplement1):16608\u201316608.","journal-title":"J Immunol"},{"issue":"1","key":"3429_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Proakis H, Ramirez D, Schick JA, Perretti M, Kagan VE, Conrad M. AcSl4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat chem Biol. 2017;13(1):91\u20138.","journal-title":"Nat chem Biol"},{"key":"3429_CR71","doi-asserted-by":"publisher","first-page":"698167","DOI":"10.3389\/fmed.2021.698167","volume":"8","author":"LS Kazi Tani","year":"2021","unstructured":"Kazi Tani LS, Gourlan AT, Dennouni-Medjati N, Telouk P, Dali-Sahi M, Harek Y, Sun Q, Hackler J, Belhadj M, Schomburg L. Copper isotopes and copper to zinc ratio as possible biomarkers for thyroid cancer. Front Med. 2021;8:698167.","journal-title":"Front Med"},{"issue":"1184","key":"3429_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/postmj\/qgad136","volume":"100","author":"Y-J Han","year":"2024","unstructured":"Han Y-J, Shao C-Y, Yao Y, Zhang Z, Fang M-Z, Gong T, Zhang Y-J, Li M. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies. Postgrad Med J. 2024;100(1184):373\u201381.","journal-title":"Postgrad Med J"},{"issue":"1","key":"3429_CR73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, Kapralov AA, Amoscato AA, Jiang J, Anthonymuthu T, Mohammadyani D, Yang Q, Proneth B, Klein-Seetharaman J, Watkins S, Bahar I, Greenberger J, Mallampalli RK, Stockwell BR, Tyurina YY, Conrad M, Bay\u0131r H. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81\u201390.","journal-title":"Nat Chem Biol"},{"issue":"7664","key":"3429_CR74","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453\u20137.","journal-title":"Nature"},{"issue":"3","key":"3429_CR75","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbrc.2016.08.124","volume":"478","author":"H Yuan","year":"2016","unstructured":"Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338\u201343.","journal-title":"Biochem Biophys Res Commun"},{"key":"3429_CR76","doi-asserted-by":"crossref","unstructured":"Han X, Wang K, Ma W, Zhu S, Guan J, Tian X, Zhao Z, Jiang L. A ketogenesis-ferroptosis axis maintains leukemic stem cell survival and leukemia progression. Cell Stem Cell; 2026.","DOI":"10.1016\/j.stem.2026.04.013"},{"key":"3429_CR77","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Peng, C., Mao, W., Yu, Z., Feng, Y., Li Y., Zhu, J., Zhao, J., Liao, D., & Sun, T. (2026). METTL3-mediated m6A modification of FDX1 confers resistance to cuproptosis and promotes hepatocellular carcinoma progression. Communications Biology, 9(1), 222","DOI":"10.1038\/s42003-025-09497-4"},{"issue":"7860","key":"3429_CR78","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597\u2013601.","journal-title":"Nature"},{"issue":"22","key":"3429_CR79","doi-asserted-by":"publisher","first-page":"e187448","DOI":"10.1172\/jci.insight.187448","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Liu H-J, Losko M, Yang YC, Yuan M, Henske EP, Asara JM, Singh M, Kwiatkowski DJ. Mitochondrial metabolic rewiring sensitizes mTORC1 inhibitor persister cells to cuproptosis. JCI insight. 2025;10(22):e187448.","journal-title":"JCI insight"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03429-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:14Z","timestamp":1791464534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":79,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3429"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03429-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"321"}}